Jenny Kinnard
Nurse Practitioner · Philadelphia, PANPI 1144972209
Payments from drug & device makers
Across 30 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$410
- Takeda Pharmaceuticals U.S.A., Inc.$55
- Evofem Biosciences, Inc.$44
- Idorsia Pharmaceuticals US Inc$40
- Axsome Therapeutics, Inc.$24
- Bausch Health US, LLC$22
- plus $74 from 4 others
What the payments were for
- Food & beverage$669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Evofem Biosciences, Inc. | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $22 |
| Exeltis, USA Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
How this compares
$669 in reported general payments places this provider in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $16,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $8,252 |
| EliquisApixaban | 17 | $6,698 |
| MyrbetriqMirabegron | 25 | $5,727 |
| Lacosamide | 25 | $4,178 |
| Pregabalin | 26 | $3,042 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $1,346 |
| Insulin Glargine-Yfgn | 52 | $1,233 |
| Fluticasone Propionate | 42 | $1,137 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $1,021 |
| Pantoprazole Sodium | 52 | $911 |
| Potassium Chloride | 20 | $776 |
| Escitalopram Oxalate | 40 | $661 |
| Haloperidol | 13 | $617 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $614 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Philadelphia
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Carolyn GrandePhiladelphia$71K
- Faith MutalePhiladelphia$62K
- Frances RogersPhiladelphia$46K
- Meghan GarabedianPhiladelphia$30K
- Victoria SherryPhiladelphia$10K
- Tracey WileyChambersburg$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.